title: Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece.
abstract: Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum fluoroquinolone rather recently introduced in certain European countries. We compared the antimicrobial potency of ulifloxacin with that of other fluoroquinolones against common urinary and respiratory bacterial pathogens. The microbial isolates were prospectively collected between January 2007 and May 2008 from patients with community-acquired infections in Greece. Minimum inhibitory concentrations (MICs) were determined for ciprofloxacin, levofloxacin, moxifloxacin (for respiratory isolates only), and ulifloxacin using the E-test method. The binary logarithms of the MICs [log2(MICs)] were compared by using the Wilcoxon signed-ranks test. A total of 409 isolates were studied. Ulifloxacin had the lowest geometric mean MIC for the 161 Escherichia coli, 59 Proteus mirabilis, and 22 Staphylococcus saprophyticus urinary isolates, the second lowest geometric mean MIC for the 38 Streptococcus pyogenes respiratory isolates (after moxifloxacin), and the third lowest geometric mean MIC for the 114 Haemophilus influenzae and the 15 Moraxella catarrhalis respiratory isolates (after ciprofloxacin and moxifloxacin). Compared with levofloxacin, ulifloxacin had lower log2(MICs) against E. coli (p < 0.001), P. mirabilis (p < 0.001), S. saprophyticus (p < 0.001), and S. pyogenes (p < 0.001). Compared with ciprofloxacin, ulifloxacin had lower log2(MICs) against P. mirabilis (p < 0.001), S. saprophyticus (p = 0.008), and S. pyogenes (p < 0.001), but higher log2(MICs) against H. influenzae (p < 0.001) and M. catarrhalis (p = 0.001). In comparison with other clinically relevant fluoroquinolones, ulifloxacin had the most potent antimicrobial activity against the community-acquired urinary isolates studied and very good activity against the respiratory isolates.
authors.affiliation: Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 15123, Marousi, Athens, Greece.
authors.forename: D E
authors.initials: DE
authors.lastname: Karageorgopoulos
authors.forename: S
authors.initials: S
authors.lastname: Maraki
authors.forename: A C
authors.initials: AC
authors.lastname: Vatopoulos
authors.forename: G
authors.initials: G
authors.lastname: Samonis
authors.forename: G C
authors.initials: GC
authors.lastname: Schito
authors.forename: M E
authors.initials: ME
authors.lastname: Falagas
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D001424:Bacterial Infections / Q000382:microbiology*; D017714:Community-Acquired Infections / Q000382:microbiology*; D004148:Dioxolanes / Q000494:pharmacology*; D005260:Female; D024841:Fluoroquinolones / Q000494:pharmacology*; D006115:Greece; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D010879:Piperazines / Q000494:pharmacology*; D011446:Prospective Studies; D012141:Respiratory Tract Infections / Q000382:microbiology*; D014552:Urinary Tract Infections / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D004148:Dioxolanes; D024841:Fluoroquinolones; D010879:Piperazines; C074191:prulifloxacin